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Abstract 
Aims 
Fibroblast growth factor (FGF) 23 is a hormone that increases urinary phosphate excretion and is a 
key regulator of renal sodium reabsorption and plasma volume. We therefore studied the role of 
plasma FGF23 in therapy optimization and outcomes in patients with worsening heart failure (HF).  
Methods and results 
We measured plasma C-terminal FGF23 levels at baseline in 2399 of the 2516 patients included in 
the BIOlogy Study to Tailored Treatment in Chronic HF (BIOSTAT-CHF) trial. The association between 
FGF23 and outcome was evaluated by Cox regression analysis.  
Median FGF23 was 218.0 [117.1-579.3] RU/ml, patients with higher FGF23 levels had a worse NYHA 
class, more signs of congestion, and were less likely to use ACE-inhibitors (ACEi) or angiotensin 
receptor blockers (ARBs) at baseline (all P<0.01). Higher FGF23 levels were independently associated 
with higher BNP, lower eGFR, the presence of edema and atrial fibrillation (all P<0.01????). In 
addition, higher FGF23 was independently associated with impaired uptitration of ACEi/ARBs, but 
not of beta-blockers. In multivariable Cox regression analysis, FGF23 was independently associated 
with all-cause mortality (hazard ratio: 1.17 (1.09-1.26) per log increase, P<0.001), and the combined 
endpoint of all-cause mortality and HF hospitalization (1.15 (1.08-1.22) per log increase, P<0.001).  
FGF23 outperformed NT-proBNP as a predictor of all-cause mortality (Harell’s c-statistic: 0.689 vs. 
0.679, respectively, P<0.001). 
Conclusion 
In patients with worsening HF, higher plasma FGF23 levels are independently associated with 
volume overload, less successful uptitration of ACEi/ARBs and an increased risk of all-cause mortality 
and HF hospitalization. 
Abbreviations 
ACEi  Angiotensin Converting Enzyme inhibitor 
ARB  Angiotensin Receptor Blocker 
BNP  Brain Natriuretic Peptide 
BIOSTAT-CHF BIOlogy Study to Tailored Treatment in Chronic Heart Failure 
CKD  Chronic Kidney Disease 
eGFR  estimated Glomerular Filtration Rate 
FGF23  Fibroblast Growth Factor 23 
HF  Heart Failure 
JVP  Jugular Venous Pressure 
NT-pro BNP N terminal pro Brain Natriuretic Peptide 
RAAS  Renin Angiotensin Aldosterone System 
 
Introduction 
The phosphaturic hormone fibroblast growth factor 23 (FGF23) is a key regulator of phosphate 
metabolism by inhibiting proximal tubular phosphate reabsorption in the kidney and suppressing the 
generation of 1,25(OH)2 vitamin D.{ADDIN RW.CITE{{40 Kovesdy,C.P. 2013}}} In patients with chronic 
kidney disease (CKD), higher FGF23 levels have been consistently associated with an increased risk of 
cardiovascular morbidity and mortality.{ADDIN RW.CITE{{401 Isakova,T. 2011; 633 Gutierrez,O.M. 
2008}}} In CKD, FGF23 seems particularly strongly linked with heart failure (HF) {ADDIN 
RW.CITE{{241 Scialla,J.J. 2014}}}, supported by mechanistic studies indicating that FGF23 is a key 
regulator of renal sodium reabsorption and plasma volume  {ADDIN RW.CITE{{231 Andrukhova,O. 
2014}}} and interacts with renin-angiotensin-aldosterone system (RAAS) activation.{ADDIN 
RW.CITE{{488 de Borst,M.H. 2013}}} Furthermore, high FGF23 levels were associated with an 
impaired response to sodium restriction and ACE-inhibition in CKD patients.{ADDIN RW.CITE{{479 
Humalda,J.K. 2015}}}  
Recently, elevated levels of FGF23 have been associated with cardiovascular mortality and incident 
HF in patients with stable ischemic heart disease.{ADDIN RW.CITE{{284 Udell,J.A. 2014}}} In chronic 
HF, it has been suggested that FGF23 is associated with disease severity and adverse 
outcome.{ADDIN RW.CITE{{42 Gruson,D. 2012; 400 Poelzl,G. 2014; 41 Plischke,M. 2012; 499 
Wohlfahrt,P. 2015}}} Data on FGF23 in worsening or acute HF are scarce, even though it has been 
suggested that FGF23 has a direct effect on sodium homeostasis and volume handling. The present 
study is the first to address the relation between FGF23, congestion, and clinical outcomes in new 
onset or worsening HF. Also, FGF23 contributes to RAAS activation and angiotensin converting 
enzyme inhibitor (ACEi) therapy has been shown to be less effective in CKD patients with high FGF23 
levels.(6,7) Therefore we subsequently studied whether FGF23 is associated with impaired 
uptitration of ACEi/angiotensin receptor blocker (ARB) therapy, a first-line therapy in patients with 
HF. We hypothesized that a higher plasma FGF23 level in patients with acute or worsening heart 
failure is associated with less successful uptitration of guideline-recommended ACEi/ARB therapy 
and adverse clinical outcomes.  
 
Methods 
Patient population 
The study design of the systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure 
(BIOSTAT-CHF) has been published previously. {ADDIN RW.CITE{{627 Voors,A.A. 2016}}} In brief, 
2516 patients with new onset or worsening heart failure with either an ejection fraction of ≤40% or 
plasma concentrations of Brain Natriuretic Peptide (BNP) >400 pg/ml and/or N terminal pro Brain 
Natriuretic Peptide (NT-proBNP) >2,000 pg/ml, and treated with furosemide ≥40mg/day or 
equivalent, who were on ≤50% of the target dose of ACEi or ARB and beta-blocker therapy were 
included in the BIOSTAT-CHF trial. The BIOSTAT-CHF trial is a large European, multicenter, 
multinational, prospective, observational study. The trial was approved by the local ethics 
committee at each participating center. All patients provided written informed consent.   
 
Study design 
Both inpatients and outpatients were enrolled, and had a visit at baseline and after 9 months of 
follow-up. During the first 3 months, the treating physician was encouraged to uptitrate ACEi/ARBs 
and beta-blockers to the target doses presented in the ESC heart failure guidelines.{ADDIN 
RW.CITE{{37 McMurray,J.J. 2012; 597 Ponikowski,P. 2016}}} Subsequently, patients were contacted 
every 6 months by telephone. At 9 months, reasons for not reaching the target dose were recorded. 
Median follow-up was 21 months. 
The endpoints selected for these analyses were all-cause mortality, and the combined endpoint of 
all-cause mortality or first occurrence of HF hospitalization. HF hospitalization was defined as 
hospitalization lasting longer than one day for which the primary reason was worsening of signs or 
symptoms of HF, requiring intravenous medications or an increased dose of oral diuretics.  
 
Laboratory measurements 
From 2516 enrolled patients, plasma FGF23 was determined in 2399 (95.3%) baseline plasma 
samples using a human C-terminal FGF23 ELISA (Immutopics, Inc., San Clemente, CA, USA). More 
details on this specific assay, such as inter-/intra-assay variation have been described 
previously.{ADDIN RW.CITE{{632 Heijboer,A.C. 2009}}} Using this assay, in a cohort of 3,107 
community-living persons ≥65 years of age median FGF23 was 70 [51-100] RU/mL.{ADDIN 
RW.CITE{{629 Ix,J.H. 2012}}} Phosphate, calcium and albumin were measured in stored samples 
using routine laboratory procedures. Renin and aldosterone were both measured using a 
RadioImmunoAssay (Renin: CisBio International; Aldosterone: IBL International). NT-proBNP was 
measured using Proseek Multiplex (Olink Biosciences AB, Uppsala, Sweden). Estimated glomerular 
filtration rate (eGFR) was calculated using the CKD-EPI eGFR formula.{ADDIN RW.CITE{{489 
Levey,A.S. 2009}}}  
 
Statistical analysis 
Data with a normal distribution are presented as mean ± standard deviation, and as frequencies and 
percentages for categorical values. Data with a skewed distribution are presented as median with 
interquartile ranges. Differences between quintiles of FGF23 were tested for significance with 
ANOVA (normal distribution), Kruskal-Wallis (skewed distribution), and Fisher’s exact test 
(categorical variables). A linear trend was statistically tested over quintiles of FGF23, after checking 
for non-linear trends. Uni- and multivariable linear regression analysis was performed with log 
transformed FGF23 as a dependent variable. Transformations were checked using multifractional 
polynomials. Multivariable linear regression analysis, including all variables with p<0.10 in 
univariable analysis were constructed via backward elimination and validated using bootstrap re-
sampling with 1,000 replicates. The model was tested for collinearity and checked by plotting 
residuals. Cox proportional hazard regression analysis was performed to examine associations with 
clinical outcomes. FGF23 was investigated as a continuous variable, and by quintiles. Multivariable 
models were adjusted for an outcome model specifically developed and validated in the BIOSTAT 
index and validation cohort with addition of markers that have previously been associated with 
FGF23 levels (renin, aldosterone, phosphate, albumin, calcium and eGFR, if not already included in 
the model).{ADDIN RW.CITE{{628 Voors,A.A. [No Information]}}}The following variable were 
included in the BIOSTAT risk model for all-cause mortality: age, urea, NT-proBNP, hemoglobin, and 
use of beta-blocker at baseline.{ADDIN RW.CITE{{628 Voors,A.A. [No Information]}}} The BIOSTAT 
risk model for heart failure hospitalization includes age, previous HF hospitalization, peripheral 
edema, systolic blood pressure, and eGFR.{ADDIN RW.CITE{{628 Voors,A.A. [No Information]}}} 
Finally, the risk model for the combined endpoint includes age, previous HF hospitalization, 
peripheral edema, systolic blood pressure, NT-proBNP, hemoglobin, HDL, sodium, and use of beta-
blocker at baseline.{ADDIN RW.CITE{{628 Voors,A.A. [No Information]}}} Interaction analyses were 
used to test significant interactions in subgroups that may affect the association between FGF23 and 
outcome. These were visualized using forest plots. Logistic regression was used to investigate the 
association between FGF23 and ACEi/ARB use, and whether target dose was reached. A two-tailed 
p-value <0.05 was considered statistically significant. All analyses were performed using R: a 
Language and Environment for Statistical Computing, version 3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria). 
 
Results 
Baseline characteristics per quintile of FGF23 are presented in table 1. Median FGF23 was 218.0 
[117.1-579.3] RU/ml. Patients with a higher FGF23 level were older, more often female, had a higher 
NYHA class, lower blood pressure, higher heart rate, and more signs of congestion (all P<0.005). All 
signs and symptoms of congestion, i.e. edema, orthopnea, jugular venous pressure (JVP), rales, and 
hepatomegaly were greater in patients with higher FGF23 levels. In addition, patients with higher 
FGF23 levels were more likely to be hospitalized with worsening heart failure, had worse renal 
function, higher (NT-pro)BNP, and renin levels (all P<0.001). Also, these patients less frequently used 
ACEi or ARBs and beta-blockers, and a significantly lower percentage used target doses of both 
drugs.  
Correlates of log transformed FGF23 in multivariable linear regression are presented in table 2. The 
multivariable model had an overall r2 of 0.466, and the variables showing the strongest association 
with higher log FGF23 levels were higher BNP, lower eGFR, the presence of atrial fibrillation and 
edema. Also, higher aldosterone levels were independently associated with higher log FGF23 levels.  
 
FGF23 and therapy optimization 
Higher levels of FGF23 were associated with lower rates of ACEi/ARB and beta-blocker use at 
baseline (table 1). Also, patients with a higher FGF23 level less frequently used guideline-
recommended doses of ACEi/ARBs and beta-blockers (table 1). Interestingly, higher log FGF23 levels 
were also inversely associated with ACEi/ARB use and dosage after 3 months of uptitration (table 3). 
This association remained significant after adjustment for baseline ACEi/ARB use, age, sex, eGFR, 
aldosterone, renin, calcium, albumin, phosphate, and NYHA class. In contrast, there was no 
significant independent association between FGF23 levels and beta-blocker use and dosage after 3 
months of uptitration (supplementary table 1). 
 FGF23 and outcomes 
During a median follow-up of 21 [16-27] months, 631 of the 2399 patients (26%) died, and 588 
patients (25%) were (re)hospitalized for heart failure. A total of 981 patients (41%) experienced the 
combined endpoint of all-cause mortality and/or heart failure hospitalization. In univariable Cox 
regression analysis, an increase in log FGF23 was significantly associated with an increased risk of the 
combined endpoint, and remained independently associated after multivariable adjustment (HR: 
1.15 [1.08-1.22] per log increase, P<0.001). Similar findings were observed in a multivariable Cox 
regression analysis as patients in the highest three quintiles of FGF23 had a significantly increased 
risk of the combined endpoint, compared to the lowest (first) quintile (table 4). The Kaplan Meier 
curve for the combined endpoint per quintile of FGF23 is shown in figure 1. Hazard ratios were 
consistent across subgroups based on ejection fraction, renal function, and RAAS activation (figure 
2). There was a significant interaction between FGF23 and age and NYHA class, yet consistently 
across these subgroups higher FGF23 levels were also associated with a higher risk of the combined 
endpoint.  Analyses are missing when adjusted for the previously published prediction model (by 
Wouter ), these should be added to make biostat-chf papers consistent. 
Higher log FGF23 levels were also independently associated with all-cause mortality in univariable 
and multivariable analyses (HR: 1.17 [1.09-1.26] per log increase, P<0.001). The Kaplan Meier per 
quintile of FGF23 for mortality is shown in supplementary figure 1. The association of higher FGF23 
with outcome for both endpoints persisted after additional adjustment for percentage of target dose 
reached after 3 months of uptitration (p<0.001 for both endpoints). The predictive value of FGF23 
for all-cause mortality was greater than that for NT-proBNP (univariable Harell’s c-statistic: 0.689 vs. 
0.679, respectively, P<.001). Stats on the additive value of FGF-23 are missing. How much better in 
the prediction or re-classificaiton of events when added. 
 Discussion 
In patients with worsening HF, higher FGF23 levels were strongly and independently associated with 
an increased risk of all-cause mortality and heart failure hospitalization. Patients with a higher FGF23 
level had more severe HF, with more signs of congestion, a greater activation of the renin-
angiotensin-aldosterone activation and worse renal function, yet the associations with outcomes 
were independent of these baseline parameters. Furthermore, patients with a higher FGF23 level 
were less well uptitrated with ACEi or ARBs during follow-up.  
FGF23 and volume overload 
FGF23 is a protein produced by osteocytes and osteoblasts, and has been identified as a 
phosphaturic hormone central to the regulation of phosphate homeostasis.{ADDIN RW.CITE{{490 
Shimada,T. 2004}}} FGF23 is deregulated in a relatively early stage of CKD, contributing to 
abnormalities in bone and mineral metabolism.{ADDIN RW.CITE{{491 Isakova,T. 2011}}} 
Interestingly, a higher level of FGF23 has emerged as a strong risk factor for cardiovascular and all-
cause mortality across the spectrum of CKD and after kidney transplantation.{ADDIN RW.CITE{{492 
Scialla,J.J. 2014; 493 Baia,L.C. 2013}}} These adverse effects of FGF23 are most likely beyond its 
direct effects on phosphate. This is suggested by the observation that hyperphosphatemia is strongly 
associated with vascular calcification and ischemic cardiac events, whereas FGF23 is strongly 
associated with HF and not with vascular calcification.{ADDIN RW.CITE{{241 Scialla,J.J. 2014; 500 
Scialla,J.J. 2013}}} Preclinical data demonstrated that FGF23 infusion leads to the development of 
left ventricular hypertrophy.{ADDIN RW.CITE{{52 Faul,C. 2011}}} Furthermore, FGF23 increased 
expression and activity of the sodium-chloride co-transporter in the distal tubule, leading to 
increased sodium uptake, volume expansion and cardiac hypertrophy.{ADDIN RW.CITE{{231 
Andrukhova,O. 2014}}} In the current study, we demonstrate that  FGF23 levels are elevated in 
worsening HF (median: 218 RU/mL) compared to previous levels reported in a community cohort 
(median: 70 RU/mL), and that higher FGF23 levels are associated with more signs of volume 
overload.{ADDIN RW.CITE{{629 Ix,J.H. 2012}}} Remarkably, all signs and symptoms of volume 
overload and congestion, i.e. edema, orthopnea, rales, elevated JVP and hepatomegaly were more 
common in patients with higher FGF23 levels. Also, in the multivariable model for FGF23, higher 
BNP, edema, hepatomegaly, and lower hemoglobin and albumin, all signs of volume overload, were 
among the strongest predictors of FGF23 levels. Whether the association between FGF23 and 
volume overload is  causal or not cannot be concluded from these observational data. Yet, in a 
recent study FGF23 did not markedly change in response to volume interventions, suggesting that 
FGF23 would more likely be a cause than a consequence of volume overload.{ADDIN RW.CITE{{634 
Humalda,J.K. 2016}}} We only measured FGF23 at baseline, and were therefore not able to capture  
the changes of  FGF23 in relation to the changes of signs of congestion and volume overload. Several 
studies showed an inverse relationship between renal function and FGF23 levels, consistent with our 
findings in worsening heart failure.{ADDIN RW.CITE{{483 Ix,J.H. 2010; 484 Gutierrez,O.M. 2009}}} Of 
note, renal impairment was one of strongest predictors of FGF23 in our cohort.  
FGF23, circulating RAAS parameters and ACEi/ARB optimization 
In the current study, we found higher renin levels in patients with higher FGF23 levels, and higher 
aldosterone was a predictor of higher FGF23 levels in multivariable analysis, suggesting more 
pronounced RAAS activation in patients with higher FGF23. This can be related to the volume 
expansion that is also associated with higher FGF23. Alternatively, the association between higher 
plasma renin levels and FGF23 levels can be explained by  the finding that FGF23 increased the 
production of renin, by suppressing the generation of 1.25(OH)2 vitamin D, which is an established 
negative regulator of renin gene expression.{ADDIN RW.CITE{{494 Li,Y.C. 2002}}} The association 
between FGF23 and RAAS-activity is of particular interest in the light of our finding that higher FGF23 
levels were also associated with lower baseline prescription rates of ACEi or ARBs and less frequent 
use of guideline recommended target dose. Additionally, patients with higher FGF23 levels were also 
less likely to use an ACEi or ARB after 3 months of uptitration, and less frequently used target doses. 
In contrast, this was not observed for beta-blockers. This  association between FGF23 and failure of 
ACEi/ARB uptitration remained significant after adjustment for baseline ACEi/ARB use, RAAS 
activation, renal function, and severity of heart failure, suggesting that FGF23 levels provide 
additional information regarding the tolerability of ACEi or ARBs. This observation may be mediated 
by impaired renal function in patients with high FGF23 levels, however the observed association 
persisted after adjustment for eGFR. Future studies should provide more insight in the relation 
between FGF23 and tolerability of RAAS blockade and effectiveness as this could be an incredibly 
interesting and applicable feature of this biomarker.     
FGF23 and outcome 
Our findings that higher FGF23 levels are related with poorer clinical outcome in patients with 
worsening signs and symptoms of heart failure are in line with three small studies in stable chronic 
heart failure patients.{ADDIN RW.CITE{{41 Plischke,M. 2012; 400 Poelzl,G. 2014; 42 Gruson,D. 
2012}}} Recently, a larger study in patients with chronic heart failure found an increased risk of 
mortality in patients with a reduced ejection fraction, but not in patients with a preserved ejection 
fraction.{ADDIN RW.CITE{{495 Koller,L. 2015}}} In our study, we showed for the first time a strong 
predictive value of higher FGF23 levels for adverse clinical outcomes, all-cause mortality and heart 
failure hospitalization in patients with worsening signs and symptoms of heart failure. In the highest 
quintile of FGF23 more than 50% of patients died during a median follow-up of 21 months. In 
contrast with previous findings in stable chronic heart failure, we did not observe a differential 
association with outcomes for patients with reduced versus preserved ejection fraction.{ADDIN 
RW.CITE{{495 Koller,L. 2015}}} We recently published a risk score that was derived from BIOSTAT-
CHF which included 42 demographic, clinical and biochemical variables.{ADDIN RW.CITE{{628 
Voors,A.A. [No Information]}}} Interestingly,  FGF23 provided significant additive predictive value of 
adverse outcome on top of this risk score, and its prognostic value was  greater than that of NT-
proBNP.  
Several mechanisms may explain the link between FGF23 and adverse outcome. FGF23 might 
increase fluid retention, and incomplete decongestion is associated with higher rehospitalization 
rates and poorer outcome. Also, higher FGF23 might reflect patients with more severe renal 
dysfunction, a strong predictor of outcome in heart failure. The association with outcome was 
however independent of markers of volume status and renal function. This observation, along with 
data that FGF23 is also associated with mortality in patients with normal kidney function, suggests 
that FGF23 is more than a marker of impaired renal function.{ADDIN RW.CITE{{485 Parker,B.D. 
2010}}} As FGF23 stimulates RAAS activity, this may cause left ventricular remodeling, fluid overload, 
and subsequently adverse outcome. Finally, we feel FGF23 is of great interest as it may prove to be a 
modifiable risk factor, as illustrated by a recent study in hemodialysis patients, showing that 
treatment with the calcimimetic cinacalcet lowered FGF23 levels by about 50%, in association with 
lower risks of cardiovascular mortality and events.{ADDIN RW.CITE{{496 Moe,S.M. 2015}}} Several 
studies, investigating the effect of phosphate binders and diet on FGF23 in CKD patients, are 
currently ongoing.  
 
Strengths and limitations 
To our knowledge this is the first study to investigate the role of FGF23 in patients with worsening 
symptoms of heart failure. Strengths of this study are the number of patients enrolled in this 
observational, European, multicenter, multinational cohort, and the extensive clinical data available, 
such as markers of RAAS activation. Limitations of this study include the observational design of this 
study, in which residual confounding potentially influenced our results. Also, data during 
hospitalization for heart failure were not available, and we were therefore not able to establish the 
association between FGF23 and efficiency of decongestion. Furthermore, we were merely able to 
describe associations, and were unable to establish causality.  
 
Future directions 
Our study showed a strong association between higher FGF23 levels and adverse clinical outcome, 
however further studies are warranted to examined the underlying pathophysiology between higher 
FGF23 levels, fluid overload, and RAAS activation in heart failure, and establish whether FGF23 is a 
cause or a consequence of fluid overload. Prospective studies targeting FGF23 levels in heart failure 
patients, for instance through cinacalcet, would shed more light on a potential causal role for FGF23 
in fluid overload and adverse clinical outcomes in acute heart failure.  
 
Conclusion 
Higher FGF23 levels are associated with more severe heart failure, worse renal function and an 
increased risk of all-cause mortality and heart failure hospitalization in patients with acute and 
worsening heart failure. In addition, higher plasma FGF23 levels are independently associated with 
less successful uptitration of guideline recommended ACEi/ARB therapy.  
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Figure legends 
Figure 1: Kaplan-Meier survival curve for the combined endpoint of all-cause 
mortality and heart failure (re)hospitalization according to quintiles of FGF23 
 
 
 
  
Figure 2: Subgroup analyses for the association of FGF23 with the combined 
endpoint 
Abbreviations: eGFR: estimated Glomerular Filtration Rate; NYHA: New York Heart Association 
 
Table 1: baseline characteristics per quintile of FGF23 
Variable Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for 
trend 
N = 481 479 479 480 480  
FGF23 82.6 [68.2-93.7] 131.6 [117.3-
147.8] 
218.0 [190.2-
253.3] 
444.4 [364.7-
579.0] 
1862.0 [1118.0-3351.0]  
Demographics       
Sex (% Male(n)) 80.5 (387) 74.5 (357) 76.2 (365) 65.8 (316) 70.6 (339) <0.001 
Age (years) 65.4±11.6 68.1±11.2 69.6±12 70.7±12.3 70.7±11.8 <0.001 
Race (% Caucasian(n)) 99.2 (477) 99.6 (477) 98.7 (473) 98.5 (473) 98.8 (474) 0.200 
BMI (kg/m2) 27.8±4.6 28.2±5.4 27.7±5.8 27.8±5.5 27.8±5.8 0.720 
Weight (kg) 82.3±16.1 83±17.9 81.4±19.6 80.7±18.4 81.3±19.4 0.118 
Height (kg) 171.9±8.8 171.4±9 171.2±9.3 169.8±9.3 170.5±8.9 0.001 
NYHA class (%(n))      <0.001 
I 5 (24) 3.5 (17) 1.7 (8) 0.8 (4) 0 (0)  
II 52.2 (251) 41.1 (197) 34.9 (167) 28.1 (135) 17.7 (85)  
III 35.8 (172) 44.9 (215) 48.6 (233) 51.5 (247) 61.3 (294)  
IV 5.4 (26) 7.3 (35) 12.1 (58) 16 (77) 18.3 (88)  
LVEF (%) 31.3±8.2 31±10.5 30.4±10.7 32.2±11.3 30±11.8 0.363 
HFPEF (%) 3.8 (17) 8.3 (36) 7.5 (32) 15.1 (65) 10.8 (45) <0.001 
Clinical Profile       
Edema (%(n)) 9.5 (35) 22.7 (90) 24 (95) 36.4 (148) 51.7 (222) <0.001 
Orthopnea (%(n)) 20.6 (99) 25.9 (124) 35.7 (171) 40.6 (194) 50.9 (244) <0.001 
Rales > 1/3 up lung fields (%(n)) 12.5 (22) 20.9 (46) 21.1 (52) 17.8 (50) 22.2 (69) 0.078 
Jugular venous pressure (%(n)) 11.6 (36) 22.8 (74) 32.8 (104) 44.8 (138) 53.4 (171) <0.001 
Hepatomegaly (%(n)) 7.5 (36) 9.8 (47) 12.6 (60) 15.7 (75) 25.1 (120) <0.001 
Third heart tone (%(n)) 8.5 (41) 7.4 (35) 10 (48) 8.8 (42) 14.4 (69) 0.002 
Systolic Blood Pressure (mmHg) 128±20.9 128.6±22.4 123.8±21.2 124±22.6 119.2±20.2 <0.001 
Diastolic Blood Pressure (mmHg) 78±11.8 76.2±13 74.4±13.4 73.2±13.9 72.4±12.5 <0.001 
Heart Rate (beats/min) 75.7±17.1 79.2±20.1 79.6±19.3 80.8±19.3 83.3±19.9 <0.001 
Hospitalization       
Type of visit (%(n))      <0.001 
Scheduled outpatient clinic 45.1 (217) 35.3 (169) 25.3 (121) 18.8 (90) 14 (67)  
Unscheduled outpatient clinic 9.8 (47) 5.4 (26) 4.2 (20) 3.5 (17) 4.2 (20)  
Inpatient hospitalization 45.1 (217) 59.3 (284) 70.6 (338) 77.7 (373) 81.9 (393)  
Reason for visit (%(n))      <0.001 
Worsening heart failure 46.4 (223) 44.1 (211) 50.1 (240) 61.7 (296) 71.2 (342)  
New onset heart failure 28.3 (136) 34.4 (165) 30.3 (145) 24.8 (119) 19.6 (94)  
Other reason 25.4 (122) 21.5 (103) 19.6 (94) 13.5 (65) 9.2 (44)  
Diuretics iv (%(n)) 95.8 (137) 99 (206) 96.6 (254) 99.1 (325) 98.6 (360) 0.074 
Inotropics iv (%(n)) 8.5 (12) 7.2 (15) 11.5 (30) 8.3 (27) 17.2 (63) 0.001 
Nitrates iv (%(n)) 34 (48) 24.6 (51) 24.8 (65) 20.2 (66) 13.9 (51) <0.001 
Heart Failure History       
Years since first diagnosis 0.4 [0.2-1.5] 3 [0.5-5.9] 0.6 [0.1-5] 3.1 [0.3-7.7] 3.9 [1-7.5] 0.287 
NYHA class prior to decompensation/worsening HF (%(n))    <0.001 
I 13.1 (63) 11.1 (53) 10.4 (50) 6.2 (30) 4.4 (21)  
II 52.2 (251) 46.6 (223) 43.4 (208) 44 (211) 43.8 (210)  
III 21 (101) 26.3 (126) 30.7 (147) 31.2 (150) 37.7 (181)  
IV 2.7 (13) 3.3 (16) 3.8 (18) 2.9 (14) 4.2 (20)  
Previous HF hospitalization (%(n)) 24.1 (116) 26.5 (127) 34.2 (164) 35.4 (170) 39.2 (188) <0.001 
Medical History       
Hypertension (%(n)) 62.8 (302) 63 (302) 63.7 (305) 63.7 (306) 58.5 (281) 0.266 
Atrial fibrillation (%(n)) 26 (125) 42.8 (205) 46.3 (222) 51.7 (248) 59.8 (287) <0.001 
Coronary artery disease (%(n)) 41.6 (200) 40.9 (196) 44.3 (212) 49.6 (238) 49.6 (238) 0.001 
Myocardial infarction (%(n)) 37 (178) 34.7 (166) 38.4 (184) 40 (192) 42.1 (202) 0.027 
PCI (%(n)) 22.2 (107) 19.6 (94) 21.9 (105) 24.4 (117) 21.5 (103) 0.596 
CABG (%(n)) 13.1 (63) 14.6 (70) 15.4 (74) 20.8 (100) 22.1 (106) <0.001 
Pacemaker (%(n)) 4.2 (20) 5.8 (28) 8.6 (41) 8.8 (42) 9 (43) 0.001 
ICD (%(n)) 7.7 (37) 5.6 (27) 5.6 (27) 9.2 (44) 12.9 (62) <0.001 
Diabetes mellitus (%(n)) 27.2 (131) 30.7 (147) 29.6 (142) 36.7 (176) 37.9 (182) <0.001 
Peripheral artery disease (%(n)) 6.9 (33) 9.2 (44) 10.9 (52) 14.6 (70) 14 (67) <0.001 
Medication       
ACE-inhibitors or Angiotensin receptor 
blockers (%(n)) 
78.8 (379) 76 (364) 76.4 (366) 67.1 (322) 62.1 (298) <0.001 
   Target dose (%(n)) 16.2 (78) 16.1 (77) 13.2 (63) 11.7 (56) 7.7 (37) <0.001 
Beta-blockers (%(n)) 85.9 (413) 86.2 (413) 84.3 (404) 80.4 (386) 78.8 (378) <0.001 
   Target dose (%(n)) 4 (19) 4.6 (22) 5.4 (26) 7.3 (35) 5.8 (28) 0.048 
Loop diuretics (%(n)) 99.2 (477) 99.4 (476) 99.4 (476) 100 (480) 99.8 (479) 0.055 
Aldosterone antagonists (%(n)) 54.5 (262) 53.9 (258) 53.7 (257) 51.5 (247) 55.2 (265) 0.897 
Laboratory values       
Hemoglobin (g/dL) 13.9 [12.9-14.8] 13.8 [12.6-14.8] 13.3 [12.1-14.6] 12.8 [11.5-14.1] 12.3 [10.9-13.7] <0.001 
Creatinine (umol/L) 87.5 [74-104] 94.4 [77.7-
117.6] 
100 [87-128] 113.6 [89.8-
150.3] 
122 [97-159.1] 0.377 
Urea (mmol/L) 8.2 [6-12.9] 9.5 [6.8-15] 11.1 [7.7-17.1] 12 [8.2-19.4] 15.7 [9.6-25.3] <0.001 
eGFR (ml/min/1.73m2) 75.9 [61.6-89.4] 64.8 [50.5-83.3] 60 [45.3-75.9] 51.2 [37.3-68.8] 47.6 [33.2-65] <0.001 
Sodium (mmol/L) 140 [138-142] 140 [138-142] 140 [138-142] 140 [137-142] 138 [136-141] <0.001 
Potassium (mmol/L) 4.3 [4-4.6] 4.3 [4-4.6] 4.2 [3.9-4.6] 4.2 [3.9-4.5] 4.2 [3.8-4.6] 0.010 
BNP (pg/mL) 223.8 [81.5-
503.9] 
645.9 [354.5-
1037.9] 
637 [507.5-975] 822.5 [450.5-
1517.2] 
1305 [872.2-2522.5] <0.001 
NT pro-BNP (ng/L) 2365.5 [1065.8-
4541.8] 
3057 [1829.5-
5221] 
3960 [2292.5-
7509.2] 
5365.5 [2810.8-
9914.2] 
7054.5 [3397.5-11861] <0.001 
Calcium (mmol/L) 1.8 [1.6-2.1] 1.8 [1.6-2.1] 1.8 [1.5-2] 1.7 [1.5-2] 1.7 [1.4-1.9] <0.001 
Phosphate (mmol/L) 0.8 [0.7-1] 0.9 [0.7-1.1] 0.9 [0.7-1] 0.9 [0.7-1] 0.9 [0.6-1.1] 0.353 
Albumine (g/L) 35 [31-40] 34 [29-40] 33 [28-38] 31 [26-36] 30 [24-34] <0.001 
Aldosterone (pg/mL) 94.9 [44-194.5] 93 [45-167] 92 [41.4-190] 88 [43-185] 106.5 [43-257] <0.001 
Renin (UI/mL) 62.8 [23.4-186.1] 81.2 [24-205.7] 90 [29.2-259.4] 95.4 [34-255.2] 134.8 [37.4-436.1] <0.001 
 
Abbreviations: BMI: Body Mass Index; BNP: Blood Natriuretic Peptide; CABG: Coronary Artery Bypass Graft; FGF23: Fibroblast Growth Factor 23; eGFR: estimated 
Glomerular Filtration Rate; HF: Heart Failure; HFpEF: Heart Failure with a Preserved Ejection Fraction; ICD: Implantable Cardiac Defibrillator; LVEF: Left Ventricular Ejection 
Fraction; NT-proBNP: N-terminal pro Blood Natriuretic Peptide; NYHA: New York Heart Association; PCI: Percutaneous Coronary Intervention.  
 
Table 2: Multivariable model for log FGF23 
Variable Beta Coeff 95% CI T value P-value 
BNP per SD 0.387 0.33-0.44 14.511 <0.001 
eGFR per SD -0.221 -0.28--0.17 -7.945 <0.001 
Atrial fibrillation 0.366 0.27-0.47 7.170 <0.001 
Edema 0.417 0.30-0.53 7.085 <0.001 
Hemoglobin per SD -0.187 -0.24--0.13 -6.589 <0.001 
Aldosterone per SD 0.146 0.10-0.20 5.800 <0.001 
ICD 0.519 0.34-0.70 5.594 <0.001 
Albumin per SD -0.328 -0.46--0.20 -4.994 <0.001 
Calcium per SD 0.306 0.18-0.43 4.845 <0.001 
NYHA III or IV 0.201 0.09-0.31 3.586 <0.001 
Hepatomegaly 0.226 0.09-0.36 3.224 0.001 
LVEF per SD -0.066 -0.12--0.01 -2.496 0.013 
Systolic blood pressure per SD -0.066 -0.12--0.01 -2.444 0.015 
Female sex 0.144 0.03-0.26 2.435 0.015 
HF hospitalization 0.151 0.03-0.27 2.404 0.016 
Heart rate per SD 0.062 0.01-0.11 2.396 0.017 
Third heart tone 0.190 0.03-0.35 2.383 0.017 
r2=0.466 
Abbreviations: BNP: Blood Natriuretic Peptide; eGFR: estimated Glomerular Filtration Rate; HF: Heart Failure; 
ICD: Implantable Cardiac Defibrillator; LVEF: Left Ventricular Ejection Fraction; NYHA: New York Heart 
Association Class; SD: Standard Deviation. 
 
Table 3: FGF23 and ACEi/ARB use after 3 months of uptitration 
 ACEi/ARB use  Target dose  
Log FGF23  OR (CI)  P-value  OR (CI)  P-value  
Univariable  0.62 (0.57-0.68)  <0.001  0.69 (0.62-0.76)  <0.001  
Multivariable*  0.79 (0.70-0.90)  <0.001  0.76 (0.65-0.87)  <0.001  
*Corrected for age, sex, eGFR, aldosterone, renin, calcium, albumin, phosphate, NYHA class, and ACEi/ARB use 
at baseline  
Abbreviations: ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CI: confidence 
interval; FGF23: Fibroblast Growth Factor 23; OR: odds ratio 
  
Table 4: Cox regression analysis for FGF23, and all-cause mortality, heart 
failure rehospitalization, and the combined endpoint 
 All-cause mortality or HF hospitalization All-cause mortality 
 Univariable Multivariable* Univariable Multivariable* 
 HR (95% CI) P-
value 
HR (95% CI) P-
value 
HR (95% CI) P-
value 
HR (95% CI) P-
value 
Log FGF23 1.49 (1.43-1.56) <0.001 1.15 (1.08-1.22) <0.001 1.57 (1.49-
1.66) 
<0.001 1.17 (1.09-
1.26) 
<0.001 
         
Quintile 1 1.0 (Reference) Ref 1.0 (Reference) Ref 1.0 (Reference) Ref 1.0 
(Reference) 
Ref 
Quintile 2 1.58 (1.22-2.06) <0.001 1.31 (0.99-1.74) 0.059 1.93 (1.34-
2.78) 
<0.001 1.57 (1.06-
2.34) 
0.025 
Quintile 3 2.28 (1.78-2.93) <0.001 1.36 (1.03-1.79) 0.031 2.16 (1.51-
3.11) 
<0.001 1.25 (0.84-
1.87) 
0.268 
Quintile 4 3.31 (2.60-4.21) <0.001 1.56 (1.19-2.06) 0.002 4.56 (3.27-
6.35) 
<0.001 1.94 (1.33-
2.84) 
<0.001 
Quintile 5 5.35 (4.24-6.75) <0.001 1.95 (1.47-2.58) <0.001 6.89 (4.99-
9.51) 
<0.001 2.10 (1.43-
3.08) 
<0.001 
*Corrected for the BIOSTAT risk model with addition of calcium, albumin, renin, aldosterone, phosphate, and 
estimated Glomerular Filtration Rate. 
Abbreviations: FGF23: Fibroblast Growth Factor 23; HF: heart failure; HR: hazard ratio; ref: reference 
Supplementary figure 1: Kaplan Meier survival curve for all-cause mortality 
according to quintiles of FGF23 
 
  
Supplementary table 1: FGF23 and beta-blocker use after 3 months of 
uptitration 
 Beta-blocker use  Target dose  
Log FGF23  OR (CI)  P-value  OR (CI)  P-value  
Univariable  0.79 [0.72-0.88]  <0.001  0.92 (0.83-1.08)  0.112  
Multivariable*  0.93 (0.47-1.08)  0.359  0.90 [0.77-1.05]  0.197  
*Corrected for age, sex, eGFR, aldosterone, renin, calcium, albumin, phosphate, NYHA class, and beta-blocker 
use at baseline  
Abbreviations: CI: confidence interval; FGF23: Fibroblast Growth Factor 23; OR: odds ratio 
 
 
 
 
